An Immunohistochemical Investigation of the Expression of XXXX Receptor Subtypes - Should Therapeutic Trials be Performed to Determine the Efficacy of @entity1943 Analogs in Treating Advanced Thyroid Malignances?

@entity1 @entity5 @entity22260 @entity71857 @entity22796 @entity22797 @entity7931 @entity1943 @entity259 @entity7932 @entity1374
UNASSIGNED: @entity1943 and its analogs through the specific receptor are known to demonstrate antiproliferative, anti-angiogenic and pro-apoptotic actions. The presence of @entity22796 -5 has not been sufficiently explored in poorly differentiated and undifferentiated @entity259 . The aim was to investigate the SSTR subtypes expression in these aggressive @entity259 . The study also discusses the usefulness of SSTR analogs as an alternative to conventional forms of therapy. Methods: The analysis was performed by immunohistochemistry on the 14 archived poorly differentiated and 4 anaplastic @entity259 . A group of benign thyroid pathologies consisting of 11 @entity1 was also included. Results: @entity22796 were found to be expressed both in benign and malignant @entity1374 , while @entity22797 was not. Expression of @entity22796 and @entity7932 was found in samples with poorly differentiated @entity259 with a score of at least 2.0 being recorded in 10 @entity5 (71.4%). For @entity7931 A the same or higher score was noted in 5/14 (35.7%), for @entity7931 B in 4/14 (28.6%) and for @entity22260 in 3/14 (21.4%) samples. @entity71857 were found to have a score of at least 2.0 in all undifferentiated @entity259 . Immunostaining of @entity22260 was observed in 50% of samples. The immunopositive reactions were observed both in the membranes and cytoplasm of the @entity259 ' cells. In some cases positive immunostaining was localized also in the endothelium of intrathyroidal blood vessels. Conclusions: The @entity1943 multiligand analogs or selective agonists could be considered alternatives to conventional therapeutic agents in aggressive @entity259 .
